Massimo Gadina1. 1. Office of Science and Technology, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Kinases inhibitors are now used for the treatment of autoimmune diseases. Here, the most recent findings related to their mechanism of action and some of the newest molecules and targets which are being investigated for autoimmune and inflammatory disorders are reviewed. RECENT FINDINGS: Similarly to p38 inhibitors, current spleen tyrosine kinase inhibitors have not fulfilled the expectations of researchers and clinicians, and will likely not be used therapeutically in autoimmunity. Bruton's tyrosine kinase inhibitors remain in the preclinical phase. Studies on the mechanism of action of successful Janus kinase (Jak) inhibitors have revealed that, apart from T and B cells, bone cells such as osteoclasts and innate immunity cells such as dendritic cells are positively affected. More specific, novel Jak inhibitors are now in clinical trials and newer Jak inhibitors are being developed. Other kinases are emerging from basic studies as potentially druggable and will surely be investigated. SUMMARY: First-generation pan-Jak inhibitors can be useful for a wide variety of diseases. They act on adaptive as well as innate immune cells and can promote tolerance. More specific inhibitors will soon be available and these may be used in a disease-specific manner.
PURPOSE OF REVIEW: Kinases inhibitors are now used for the treatment of autoimmune diseases. Here, the most recent findings related to their mechanism of action and some of the newest molecules and targets which are being investigated for autoimmune and inflammatory disorders are reviewed. RECENT FINDINGS: Similarly to p38 inhibitors, current spleen tyrosine kinase inhibitors have not fulfilled the expectations of researchers and clinicians, and will likely not be used therapeutically in autoimmunity. Bruton's tyrosine kinase inhibitors remain in the preclinical phase. Studies on the mechanism of action of successful Janus kinase (Jak) inhibitors have revealed that, apart from T and B cells, bone cells such as osteoclasts and innate immunity cells such as dendritic cells are positively affected. More specific, novel Jak inhibitors are now in clinical trials and newer Jak inhibitors are being developed. Other kinases are emerging from basic studies as potentially druggable and will surely be investigated. SUMMARY: First-generation pan-Jak inhibitors can be useful for a wide variety of diseases. They act on adaptive as well as innate immune cells and can promote tolerance. More specific inhibitors will soon be available and these may be used in a disease-specific manner.
Authors: Katrin Friedbichler; Marc A Kerenyi; Boris Kovacic; Geqiang Li; Andrea Hoelbl; Saliha Yahiaoui; Veronika Sexl; Ernst W Müllner; Sabine Fajmann; Sabine Cerny-Reiterer; Peter Valent; Hartmut Beug; Fabrice Gouilleux; Kevin D Bunting; Richard Moriggl Journal: Blood Date: 2010-05-27 Impact factor: 22.113
Authors: Timothy P LaBranche; Michael I Jesson; Zaher A Radi; Chad E Storer; Julia A Guzova; Sheri L Bonar; Janice M Thompson; Fernando A Happa; Zachary S Stewart; Yutian Zhan; Chris S Bollinger; Prashant N Bansal; Jeremy W Wellen; Dean P Wilkie; Steven A Bailey; Peter T Symanowicz; Martin Hegen; Richard D Head; Nandini Kishore; Gabriel Mbalaviele; Debra M Meyer Journal: Arthritis Rheum Date: 2012-11
Authors: Lichuan Liu; Julie Di Paolo; Jim Barbosa; Hong Rong; Karin Reif; Harvey Wong Journal: J Pharmacol Exp Ther Date: 2011-04-26 Impact factor: 4.030
Authors: Dalya R Soond; Elisa Bjørgo; Kristine Moltu; Verity Q Dale; Daniel T Patton; Knut Martin Torgersen; Fiona Galleway; Breda Twomey; Jonathan Clark; J S Hill Gaston; Kjetil Taskén; Peter Bunyard; Klaus Okkenhaug Journal: Blood Date: 2010-01-15 Impact factor: 22.113
Authors: Jun Liang; Anne van Abbema; Mercedesz Balazs; Kathy Barrett; Leo Berezhkovsky; Wade Blair; Christine Chang; Donnie Delarosa; Jason DeVoss; Jim Driscoll; Charles Eigenbrot; Nico Ghilardi; Paul Gibbons; Jason Halladay; Adam Johnson; Pawan Bir Kohli; Yingjie Lai; Yanzhou Liu; Joseph Lyssikatos; Priscilla Mantik; Kapil Menghrajani; Jeremy Murray; Ivan Peng; Amy Sambrone; Steven Shia; Young Shin; Jan Smith; Sue Sohn; Vickie Tsui; Mark Ultsch; Lawren C Wu; Yisong Xiao; Wenqian Yang; Judy Young; Birong Zhang; Bing-yan Zhu; Steven Magnuson Journal: J Med Chem Date: 2013-05-29 Impact factor: 7.446
Authors: F Yesim Demirci; Xingbin Wang; David L Morris; Eleanor Feingold; Sasha Bernatsky; Christian Pineau; Ann Clarke; Rosalind Ramsey-Goldman; Susan Manzi; Timothy J Vyse; M I Kamboh Journal: J Med Genet Date: 2017-03-13 Impact factor: 6.318
Authors: So Jin Bing; Cancan Lyu; Biying Xu; Wambui S Wandu; Samuel J Hinshaw; Yasuko Furumoto; Rachel R Caspi; Massimo Gadina; Igal Gery Journal: Mol Vis Date: 2020-09-26 Impact factor: 2.367